Key result
Strict BP control and RAAS suppression prevent CKD and CVD progression.
Why the study?
The optimal blood pressure targets and antihypertensive treatment strategies in patients with CKD remain uncertain and require further study.
Population
Patients with arterial hypertension and chronic kidney disease
Comparison
Antihypertensive therapies including ACEi/ARB, calcium channel blockers, and diuretics
Design
Review
Authors
Loading...
BP targets <130/80 mmHg in albuminuric CKD remain debated; leaves open optimal thresholds for renal and CV protection.
Blood pressure control, typically initiated with an ACEi or ARB, is crucial in patients with CKD to reduce global cardiovascular risk and protect kidney function.
Márquez et al. (2017) conducted a review in Chronic kidney disease and arterial hypertension. Antihypertensive therapy was evaluated. Strict blood pressure control, RAAS suppression, and an integrated approach to cardiovascular risk are required to prevent the progression of chronic kidney disease and cardiovascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: